Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1970 1
1971 1
1974 1
1975 2
1976 2
1977 2
1978 1
1979 2
1980 1
1981 3
1982 5
1983 11
1984 9
1985 6
1986 19
1987 31
1988 17
1989 23
1990 32
1991 31
1992 34
1993 41
1994 40
1995 31
1996 62
1997 35
1998 35
1999 43
2000 36
2001 48
2002 47
2003 66
2004 44
2005 52
2006 56
2007 61
2008 61
2009 63
2010 76
2011 77
2012 90
2013 79
2014 96
2015 98
2016 103
2017 89
2018 78
2019 94
2020 122
2021 145
2022 154
2023 109
2024 53

Text availability

Article attribute

Article type

Publication date

Search Results

2,312 results

Results by year

Filters applied: . Clear all
Page 1
Immunoglobulin replacement therapy in primary and secondary antibody deficiency: The correct clinical approach.
Pecoraro A, Crescenzi L, Granata F, Genovese A, Spadaro G. Pecoraro A, et al. Int Immunopharmacol. 2017 Nov;52:136-142. doi: 10.1016/j.intimp.2017.09.005. Epub 2017 Oct 12. Int Immunopharmacol. 2017. PMID: 28898770 Review.
Immunoglobulin therapy is the administration of human polyvalent IgG and represents the most effective treatment to prevent recurrent infections in antibody deficiency patients. ...In addition, we propose a clinical approach, mainly based on the evaluation of infect …
Immunoglobulin therapy is the administration of human polyvalent IgG and represents the most effective treatment to prevent re …
How We Treat Autoimmune Small Fiber Polyneuropathy with Immunoglobulin Therapy.
Schofield JR, Chemali KR. Schofield JR, et al. Eur Neurol. 2018;80(5-6):304-310. doi: 10.1159/000498858. Epub 2019 Mar 19. Eur Neurol. 2018. PMID: 30889595 Free article. Review.
Intravenous immunoglobulin therapy is FDA approved for the immune-mediated peripheral nerve disorders Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. Immunoglobulin therapy has been used incr …
Intravenous immunoglobulin therapy is FDA approved for the immune-mediated peripheral nerve disorders Guillain-Barre syndrome, …
Immunoglobulin therapy.
[No authors listed] [No authors listed] Lancet. 1991 Jul 20;338(8760):157-8. Lancet. 1991. PMID: 1677073 No abstract available.
Intravenous immunoglobulin therapy.
Chapel H. Chapel H. QJM. 1996 Sep;89(9):641-3. doi: 10.1093/qjmed/89.9.641. QJM. 1996. PMID: 8917738 No abstract available.
Immunoglobulin therapy.
Finlayson JS, Tankersley DL. Finlayson JS, et al. Lancet. 1991 Oct 5;338(8771):893-4. doi: 10.1016/0140-6736(91)91558-c. Lancet. 1991. PMID: 1681255 No abstract available.
Immunoglobulin therapy in bone marrow transplantation.
Sullivan KM. Sullivan KM. Am J Med. 1987 Oct 23;83(4A):34-45. doi: 10.1016/0002-9343(87)90549-3. Am J Med. 1987. PMID: 2823602 Review.
However, patients in whom chronic graft-versus-host disease (GVHD) develops have persisting B and T cell abnormalities, and in vivo and in vitro studies show impaired immunoglobulin regulation and function despite normal levels of serum immunoglobulin G. This review summarizes 12 …
However, patients in whom chronic graft-versus-host disease (GVHD) develops have persisting B and T cell abnormalities, and in vivo and in v …
2,312 results